Novel marginal zone lymphoma models of resistance to the dual inhibition of PI3K and BCL2

被引：0
|
作者：
Arribas, Alberto J.
Cascione, Luciano
Cannas, Eleonora
Bellerjeau, Helen
Fuzio, Federica
Noguera, Aleix
Rinaldi, Andrea
Esteller, Manel
Zucca, Emanuele
Alimonti, Andrea
Rossi, Davide
Stathis, Anastasios
Bertoni, Francesco
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
534
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Improving responses to dual PI3K/BCL2 inhibition in lymphomas: results of a pharmacological screen with over 1,400 compounds
    Arribas, A.
    Chiappa, M.
    Napoli, S.
    Cannas, E.
    Cascione, L.
    Spriano, F.
    Tarantelli, C.
    Rossi, D.
    Zucca, E.
    Alimonti, A.
    Stathis, A.
    Damia, G.
    Broggini, M.
    Bertoni, F.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S107 - S108
  • [12] Successful inhibition of PI3K, BTK, BCL2 and other targets in various B-cell malignancies
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (SUPPL 6) : 127 - 131
  • [13] Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
    Arribas, Alberto J.
    Napoli, Sara
    Cascione, Luciano
    Sartori, Giulio
    Barnabei, Laura
    Gaudio, Eugenio
    Tarantelli, Chiara
    Mensah, Afua Adjeiwaa
    Spriano, Filippo
    Zucchetto, Antonella
    Rossi, Francesca M.
    Rinaldi, Andrea
    de Moura, Manuel Castro
    Jovic, Sandra
    Bordone-Pittau, Roberta
    Di Veroli, Alessandra
    Stathis, Anastasios
    Cruciani, Gabriele
    Stussi, Georg
    Gattei, Valter
    Brown, Jennifer R.
    Esteller, Manel
    Zucca, Emanuele
    Rossi, Davide
    Bertoni, Francesco
    HAEMATOLOGICA, 2022, 107 (11) : 2685 - 2697
  • [14] Unrelated Clones and Acquired BCL2 Gene Abnormalities in Cutaneous Marginal Zone Lymphoma
    Yuen, H.
    Palmer, T.
    Sproul, A.
    Paterson, M.
    Hendry, L.
    Day, F.
    Sales, M.
    Pratt, N.
    Batstone, P.
    Goodlad, J.
    JOURNAL OF PATHOLOGY, 2010, 222 : S26 - S26
  • [15] Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML
    Vachhani, Pankit
    Bose, Prithviraj
    Rahmani, Mohamed
    Grant, Steven
    PHYSIOLOGICAL GENOMICS, 2014, 46 (13) : 448 - 456
  • [16] Resistance to PI3K delta inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
    Arribas, Alberto J.
    Napoli, Sara
    Cascione, Luciano
    Sartori, Giulio
    Barnabei, Laura
    Gaudio, Eugenio
    Tarantelli, Chiara
    Mensah, Afua Adjeiwaa
    Spriano, Filippo
    Zucchetto, Antonella
    Rossi, Francesca M.
    Rinaldi, Andrea
    Moura, Manuel Castro de
    Jovic, Sandra
    Bordone-Pittau, Roberta
    Di Veroli, Alessandra
    Stathis, Anastasios
    Cruciani, Gabriele
    Stussi, Georg
    Gattei, Valter
    Brown, Jennifer R.
    Esteller, Manel
    Zucca, Emanuele
    Rossi, Davide
    Bertoni, Francesco
    HAEMATOLOGICA, 2022, 107 : 2685 - 2697
  • [17] Dual PI3K/BCL-2 family inhibition in colorectal cancers with Apc and Pik3camutations
    Miller, Devon D.
    Babiarz, Christopher P.
    Payne, Susan N.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Deming, Dustin A.
    CANCER RESEARCH, 2018, 78 (13)
  • [18] PI3K inhibition in preclinical models of HNSCC
    Hedberg, Matthew Louis
    Li, Hua
    Zeng, Yan
    Grandis, Jennifer Rubin
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [19] Dual PI3K and mTOR Inhibition in Waldenstrom Macroglobulinemia
    Husu, E. N.
    Roccaro, A. M.
    Anderson, K. C.
    Ghobrial, I. M.
    Leleu, X.
    Sacco, A.
    Melhem, M. R.
    Azab, A. K.
    Jia, X.
    Ngo, H. T.
    Azab, F.
    Runnels, J.
    Quang, P.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S144 - S145
  • [20] Dual inhibition of EGFR and PI3K with a single drug
    Katerji, Meghri
    Rubin, Maxine R.
    Brognard, John
    NATURE CANCER, 2024, 5 (08) : 1131 - 1133
12345